體內CRO市場：按類型、服務類型、模式、適應症和最終用戶分類－2026-2032年全球市場預測

預計到 2025 年，體內 CRO 市場價值將達到 65.8 億美元，到 2026 年將成長至 72.1 億美元，到 2032 年將達到 128.8 億美元，年複合成長率為 10.06%。

主要市場統計數據
基準年 2025	65.8億美元
預計年份：2026年	72.1億美元
預測年份：2032年	128.8億美元
複合年成長率 (%)	10.06%

策略實施概述了塑造當今體內CRO的不斷演變的優先事項和營運動態

體內合約研究領域處於科學複雜性和操作嚴謹性的交匯點，轉化準確性和合規性對於專案的持續進行至關重要。隨著申辦方致力於生技藥品、基因療法和新一代治療方法的研發，對可靠的臨床前模型和一體化服務管道的需求日益成長。為此，各機構正在重組，以更快地提供更高品質的數據，同時確保符合日益嚴格的動物福利和生物安全標準。

分析正在重塑 In Vivo 合約研究服務營運、技術和監管預期的變革性變化。

該領域正經歷一系列相互交織的變革，這些變革正在重塑研究的設計、進行和解讀方式。首先，成像、遙測和體內生物標記技術的成熟，使得更豐富、更具轉化價值的資料集得以生成，從而減少了對單一終點研究的依賴，並促進了縱向研究設計。其次，生技藥品和基因編輯技術的進步帶來了新的安全考量，需要製定量身定做的毒理學策略並對設施進行改造，以安全地應對這些複雜性。

彙編了關於 2025 年美國關稅政策變化對生物研究提供者的供應鏈、成本結構和戰略運營的影響的定性評估。

美國2025年關稅政策的轉變，使得整個生物研究生態系對供應鏈韌性的關注日益提高。專業耗材、設備零件以及某些動物飼養用品的採購通常依賴全球採購，而關稅調整會給採購計畫帶來不確定性。因此，供應商正在重新評估供應商所在地，尋找替代供應商，並建立庫存緩衝，以確保檢驗的連續性。這些應對措施優先考慮冗餘備份和經過驗證的替代供應商，以減少中斷。

深入的細分分析揭示了能力深度、模式專業化以及與最終用戶的關係如何為整個生物醫​​學研究市場提供明顯的競爭優勢。

差異化始於生物模型的專業化。按非囓齒類和囓齒類模型類型進行細分，會造成設施需求、獸醫專業知識和監管管道方面的差異。在非囓齒類模型方面擁有豐富經驗的機構通常在複雜的外科手術能力和長期藥物動力學監測方面表現出色，而囓齒類模型方面的專業知識則支持高性能篩檢和早期概念驗證(PoC) 工作。同時，服務類型的細分——從臨床服務和諮詢策略到實驗室服務、臨床前服務、監管服務以及毒性和安全性評估——在諮詢服務提供者和以執行為導向的供應商之間劃清了界限。將諮詢服務與實踐性毒性測試和符合良好實驗室規範 (GLP) 的實驗室服務相結合的公司，能夠提供差異化服務，從而減少轉化研究的阻力。

區域洞察揭示了地理趨勢、法規結構和人才生態系統如何影響全球主要區域的需求、產能分佈和夥伴關係模式。

地理環境對商業模式和策略重點有顯著影響。在美洲，清晰的監管環境、完善的GLP基礎設施以及與主要申辦公司總部的接近性，為複雜且高度合規的項目提供了支持，並促進了申辦方與CRO之間的頻繁合作。這種環境有利於擁有健全的品管體系，並能依照IND/CTA申報要求進行後期臨床前包裝的供應商。相較之下，歐洲、中東和非洲的管理體制和研究生態系統各不相同，區域協調努力與區域特定的合規要求並存。這些地區的供應商通常優先考慮柔軟性、跨司法管轄區的經驗以及與學術機構的合作以獲得專業知識。在跨國計畫中，人才招募和跨境物流是關鍵的考量。

本報告深入分析了企業能力和策略行動，展示了領導企業、專業公司和新興參與企業如何透過投資、夥伴關係和卓越營運來提升自身競爭力。

領先機構正在展現出能夠帶來競爭優勢的能力建構和協作模式。首先，對平台技術和檢驗工作流程的投資能夠提高可重複性，縮短營運週期，並最終支援更複雜的專案。其次，將諮詢、測試設計和法規聯絡服務與良好實驗室規範 (GLP) 實施相結合的公司能夠創造無縫的客戶體驗並降低轉換風險。第三，與學術機構、儀器製造商和專業實驗室建立策略夥伴關係，能夠在不產生大量固定成本的情況下利用專業領域的專長，從而使申辦方能夠獲得靈活的資源。

為幫助產業領導者增強韌性、提高轉換保真度、加速臨床前開發階段的專案決策，提供切實可行的優先建議。

首先，優先投資於檢驗的平台技術和資料系統，以確保資料集的可重複性和可審計性，並支援不同測試之間的比較。這有助於減少下游流程的不確定性，並增強監管機構的信心。其次，透過諮詢型測試設計服務，加強與申辦者的上游合作，使臨床前終點與臨床目標一致。這種合作方式可以降低測試設計修改的風險，並縮短開發週期。第三，透過供應商多元化和協商靈活的採購條款，降低供應鏈中斷和政策變化帶來的風險。確保有備選供應商並維持充足的庫存緩衝，可以在不大幅增加固定成本的情況下保障業務永續營運。

本文檔概述了用於在生物研究領域得出嚴謹且可操作的見解的資料來源、分析框架和檢驗程序，展示了高度透明的調查方法。

本分析整合了多方面的證據，以得出平衡且檢驗的結論。主要資訊來源包括對行業領導者、獸醫病理學和毒理學專家以及負責臨床前開發的高級專案主管的結構化訪談。這些定性對話深入探討了營運挑戰、能力投資和夥伴關係重點。為補充主要研究，我們還系統地回顧了監管指南、同行評審的科學文獻和公共公告，以提供有關合規趨勢、新興模型系統和動物福利標準的背景資訊。

一份權威的綜合分析報告，重點闡述了將決定活體組織切片提供者和贊助商專案成敗的策略挑戰和營運重點。

大量證據表明，生物醫學研究中最關鍵的差異化因素在於可重複資料的產生、綜合諮詢服務以及穩健的營運網路。能夠將諮詢式測試設計、檢驗的實施平台和嚴格的品管系統結合的供應商，最能應對複雜的試驗模式和特定適應症的需求。同時，申辦方也能從選擇能夠預見監管預期、應對供應鏈波動並提供透明且可審計的資料集的合作夥伴中獲益匪淺，從而加快審查和決策進程。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 工業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：體內CRO市場：依類型分類

• 不囓齒類動物
• 囓齒動物

第9章：體內CRO市場：依服務類型分類

• 臨床服務
• 諮詢策略
• 檢查服務
• 臨床前服務
• 監管服務
• 毒性和安全性評估

第10章：體內CRO市場：依模式分類

• 聚合物化合物
• 低分子化合物

第11章 體內CRO市場：依適應症分類

• 心血管疾病
  • 冠狀動脈疾病
  • 心臟衰竭
• 感染疾病
  • 細菌感染疾病
  • 病毒感染疾病
• 神經系統疾病
  • 神經退化性疾病
  • 精神疾病
• 腫瘤學
  • 骨髓惡性腫瘤
  • 固體癌
• 呼吸系統疾病
  • 氣喘
  • 慢性阻塞性肺病

第12章 體內CRO市場：依最終用戶分類

• 學術和研究機構
• 政府和監管機構
• 醫療設備製造商
• 製藥和生物技術公司

第13章 體內CRO市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 體內CRO市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 體內CRO市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國體內CRO市場

第17章：中國體內CRO市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Altogen Labs
• Biocytogen Boston Corp.
• Cellvax, SAS
• Charles River Laboratories International, Inc.
• Crown Bioscience, Inc.
• Eurofins Scientific SE
• Evotec SE
• Explicyte（Immusmol SAS Company）
• GEMPHARMATECH LLC
• ICON Plc
• Imavita SAS
• IQVIA Holdings Inc.
• IVRS AB
• JSR Corporation
• Labcorp Drug Development PRIVATE LIMITED
• Medpace, Inc.
• Melior Discovery Inc.
• Noble Life Sciences Inc.
• Parexel International Corporation
• Pharmacology Discovery Services Ltd.
• Pharmaron Beijing Co., Ltd.
• Pharmatest Services Ltd.
• PPD Inc.（Thermo Fisher Scientific, Inc.）
• PSI CRO AG
• Syneos Health Inc.
• Syngene International Limited
• Taconic Biosciences, Inc.
• WuXi AppTec, Inc.
• Yecuris Corporation

The In Vivo CRO Market was valued at USD 6.58 billion in 2025 and is projected to grow to USD 7.21 billion in 2026, with a CAGR of 10.06%, reaching USD 12.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 6.58 billion
Estimated Year [2026]	USD 7.21 billion
Forecast Year [2032]	USD 12.88 billion
CAGR (%)	10.06%

Strategic introduction framing the evolving priorities and operational dynamics shaping in vivo contract research organizations today

The in vivo contract research landscape sits at the intersection of scientific complexity and operational rigor, where translational fidelity and regulatory alignment determine program continuity. As sponsors pursue biologics, gene therapies, and next-generation modalities, demand for robust preclinical models and integrated service pathways has intensified. In response, organizations are reconfiguring capabilities to deliver higher quality data with faster turnarounds while maintaining compliance with tightening animal welfare and biosafety standards.

Moreover, cross-functional collaboration between preclinical teams, toxicologists, and regulators has become a central operational philosophy. This alignment supports more predictable study designs and smoother handoffs into clinical development. Consequently, leading providers are investing in platform technologies, data integrity protocols, and personnel training to sustain reproducibility and traceability across study lifecycles.

Transitioning from historical silos to integrated service models, the sector now prioritizes end-to-end solutions that reduce translational risk. Stakeholders evaluating partnerships increasingly favor providers who combine deep in vivo expertise with consultative design capabilities, regulatory acumen, and a demonstrable track record of quality systems.

Analysis of transformative shifts rewriting operational, technological, and regulatory expectations across in vivo contract research services

The sector is undergoing a set of converging shifts that are reshaping how studies are designed, executed, and interpreted. First, technological maturation in imaging, telemetry, and in vivo biomarkers enables richer, more translational datasets, reducing the reliance on single-endpoint studies and encouraging longitudinal designs. Second, advances in biologic modalities and gene editing have introduced novel safety considerations that require bespoke toxicology strategies and facility adaptations to manage complexity safely.

Concurrently, regulatory agencies worldwide are harmonizing expectations around data integrity, animal welfare, and study reproducibility. These policy movements increase the emphasis on GLP-grade operations, validated systems, and transparent data capture. As a result, providers must demonstrate rigorous quality systems and invest in staff competencies to remain competitive.

Finally, commercial dynamics are shifting toward collaborative development models where sponsors, CROs, and academic partners coordinate earlier and more closely. This collaborative posture accelerates decision cycles and reduces costly rework. Taken together, these trends are elevating the role of consultative CRO partners who can integrate experimental design, execution excellence, and regulatory foresight into cohesive programs.

Cumulative qualitative assessment of how evolving United States tariff policies in 2025 influence supply chains, cost structures, and strategic operations for in vivo research providers

Shifts in U.S. tariff policies in 2025 have amplified attention on supply chain resilience across the in vivo research ecosystem. Procurement of specialized consumables, equipment components, and certain animal husbandry supplies often relies on global sourcing, and tariff adjustments introduce uncertainty into procurement planning. Consequently, providers are reassessing supplier footprints, seeking alternative vendors, and building inventory buffers to maintain study continuity. These operational responses prioritize redundancy and validated secondary suppliers to mitigate disruption.

In addition to direct cost pressures, tariffs reshuffle comparative advantages between domestic manufacturing and imported goods, influencing capital investment decisions for facility upgrades and local production capabilities. In response, some organizations accelerate capital projects that reduce foreign dependence, while others pursue contracting terms and hedging strategies to insulate programs from near-term price volatility. Furthermore, tariff dynamics ripple through contract structuring, prompting more explicit pass-through clauses and renegotiation frameworks to allocate commercial risk between sponsors and providers.

Overall, the supply chain and commercial planning implications of tariff policy changes underscore the importance of proactive procurement strategies, diversified supplier ecosystems, and contractual clarity to preserve schedule integrity and research continuity.

Insightful segmentation analysis revealing where capability depth, modality focus, and end-user relationships create distinct competitive advantages across the in vivo research market

Differentiation begins with biological model specialization: Type segmentation between Non-Rodent and Rodent models drives variations in facility requirements, veterinary expertise, and regulatory pathways. Organizations with deep experience in non-rodent models often command complex surgical capabilities and extended pharmacokinetic monitoring, while rodent expertise supports high-throughput screening and early proof-of-concept work. In parallel, service type segmentation-ranging from Clinical Services and Consulting & Strategy to Laboratory Services, Preclinical Services, Regulatory Services, and Toxicological & Safety Assessment-creates clear lines between consultative providers and execution-focused vendors. Firms that combine consulting with hands-on toxicology and GLP laboratory services create differentiated offerings that reduce translational friction.

Modality focus between Large Molecules and Small Molecules further shapes operational design; biologics demand specific handling, immunogenicity assessment, and dosing paradigms, whereas small molecule programs emphasize ADME characterization and metabolic profiling. Indication segmentation across Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Oncology, and Respiratory Disorders introduces therapeutic-area specific model needs and endpoint complexity. Within indications, subcategories such as coronary artery disease and heart failure, bacterial and viral infections, neurodegenerative and psychiatric disorders, hematological malignancies and solid tumors, and asthma and COPD require tailored endpoints, disease modeling expertise, and specialized pathology capabilities. Finally, end-user segmentation encompassing Academic & Research Institutions, Government & Regulatory Organizations, Medical Device Companies, and Pharmaceuticals & Biotechnology Companies determines project cadence, compliance expectations, and reporting depth. Sponsors from academic settings often prioritize exploratory flexibility, whereas industry and regulatory customers demand higher documentation rigor and predictable timelines.

Regional insights that clarify how geographic dynamics, regulatory frameworks, and talent ecosystems influence demand, capability distribution, and partnership models across major global territories

Geographic context significantly shapes operational models and strategic priorities. In the Americas, regulatory clarity, established GLP infrastructure, and proximity to major sponsor headquarters support complex, high-compliance programs and facilitate frequent sponsor-CRO interaction. This environment favors providers with strong quality management systems and capabilities to run late-stage preclinical packages that align closely with IND/CTA submissions. Conversely, Europe, Middle East & Africa present a mosaic of regulatory regimes and research ecosystems where regional harmonization initiatives coexist with localized compliance requirements. Providers in this region often emphasize flexibility, multi-jurisdictional experience, and collaborations with academic centers to access specialized expertise. Talent availability and cross-border logistics are key considerations for multinational programs.

Asia-Pacific offers a rapidly expanding base of research capacity, driven by investments in laboratory infrastructure, growing local pharmaceutical industries, and cost competitiveness for certain services. However, sponsors and providers navigating this region must account for variable regulatory expectations, differences in animal welfare practices, and logistical complexity. As a result, cross-regional programs typically rely on strong governance models and centralized data standards to ensure consistency. Collectively, these regional dynamics influence where providers invest, how they structure global networks, and which partnership models best support sponsor objectives.

Company capability and strategic behavior insights that indicate how leaders, specialists, and emerging entrants create competitive differentiation through investments, partnerships, and operational excellence

Leading organizations demonstrate patterns of capability building and collaboration that translate into competitive advantage. First, investment in platform technologies and validated workflows enhances reproducibility and shortens operational cycles, which in turn supports higher-complexity programs. Second, firms that integrate consulting, study design, and regulatory liaison services with GLP execution create a seamless client experience that reduces translational risk. Third, strategic partnerships with academic centers, instrumentation providers, and specialty labs enable access to niche expertise without the full fixed-cost investment, facilitating flexible resourcing for sponsors.

Additionally, successful providers emphasize talent development and cross-disciplinary teams that combine veterinary medicine, pathology, pharmacology, and data science. This multidisciplinary approach improves endpoint selection, data interpretation, and risk mitigation. Finally, companies pursuing geographic diversification leverage regional strengths-such as specialized disease model expertise or cost-effective operational nodes-to create resilient delivery networks. Together, these behaviors highlight the routes by which companies scale capability while managing scientific and commercial risk.

Practical, prioritized recommendations that enable industry leaders to strengthen resilience, improve translational fidelity, and accelerate program decision-making across preclinical development

First, prioritize investment in validated platform technologies and data systems that ensure reproducible, auditable datasets and support cross-study comparisons. Doing so reduces downstream ambiguity and enhances regulatory confidence. Second, build stronger upstream engagement with sponsors through consultative study design services that align preclinical endpoints with clinical objectives; this collaborative stance reduces redesign risk and shortens development cycles. Third, diversify supplier footprints and negotiate flexible procurement terms to mitigate exposure to supply chain shocks and policy changes. Implementing secondary sourcing and targeted inventory buffers supports continuity without unduly raising fixed costs.

Fourth, enhance workforce capabilities by cross-training staff in contemporary modalities, welfare standards, and GLP practices, thereby increasing operational agility. Fifth, formalize partnership models with academic centers and specialty labs to access niche expertise while maintaining core operational focus. Finally, update commercial contracts to clarify cost escalation mechanisms and risk allocation in the face of tariff or logistic volatility. These prioritized actions combine to increase resilience, improve translational alignment, and protect program timelines.

Transparent research methodology outlining data sources, analytical frameworks, and validation steps used to develop rigorous, actionable insights for the in vivo research sector

This analysis synthesizes multiple evidence streams to ensure balanced and verifiable conclusions. Primary inputs include structured interviews with industry leaders, subject matter experts in veterinary pathology and toxicology, and senior program directors responsible for preclinical development. These qualitative engagements informed perspectives on operational challenges, capability investments, and partnership priorities. Complementing primary research, a systematic review of regulatory guidance, peer-reviewed scientific literature, and public policy announcements provided context on compliance trends, emerging model systems, and welfare standards.

Analytical methods incorporated thematic coding of qualitative data and cross-case comparison to identify recurring patterns and divergent practices. Validation occurred through triangulation across sources and targeted follow-up discussions to resolve inconsistencies. Throughout, emphasis was placed on procedural transparency, careful attribution of inferential leaps, and clear articulation of assumptions. The methodology balances depth of practitioner insight with a robust review of publicly available technical and regulatory material to deliver credible, actionable findings.

Conclusive synthesis emphasizing the strategic imperatives and operational priorities that will determine program success for in vivo research providers and sponsors alike

The cumulative evidence indicates that the most consequential differentiators in in vivo research will be reproducible data generation, integrated advisory services, and resilient operational networks. Providers that blend consultative study design, validated execution platforms, and disciplined quality systems will be best positioned to support complex modalities and indication-specific requirements. Simultaneously, sponsors benefit from choosing partners who can anticipate regulatory expectations, manage supply chain variability, and deliver transparent, auditable datasets that accelerate reviews and decisions.

Looking forward, organizations that invest in multidisciplinary talent, platform validation, and flexible partnerships will reduce translational uncertainty and maintain program cadence in the face of external disruptions. In short, strategic focus on quality, collaboration, and resilience will differentiate leaders and enable more predictable progression from preclinical insights to clinical milestones.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In Vivo CRO Market, by Type

• 8.1. Non-Rodent
• 8.2. Rodent

9. In Vivo CRO Market, by Service Type

• 9.1. Clinical Services
• 9.2. Consulting & Strategy
• 9.3. Laboratory Services
• 9.4. Preclinical Services
• 9.5. Regulatory Services
• 9.6. Toxicological & Safety Assessment

10. In Vivo CRO Market, by Modality

• 10.1. Large Molecules
• 10.2. Small Molecules

11. In Vivo CRO Market, by Indication

• 11.1. Cardiovascular Diseases
  • 11.1.1. Coronary Artery Disease
  • 11.1.2. Heart Failure
• 11.2. Infectious Diseases
  • 11.2.1. Bacterial Infections
  • 11.2.2. Viral Infections
• 11.3. Neurological Disorders
  • 11.3.1. Neurodegenerative Disorders
  • 11.3.2. Psychiatric Disorders
• 11.4. Oncology
  • 11.4.1. Hematological Malignancies
  • 11.4.2. Solid Tumors
• 11.5. Respiratory Disorders
  • 11.5.1. Asthma
  • 11.5.2. Chronic Obstructive Pulmonary Disease

12. In Vivo CRO Market, by End User

• 12.1. Academic & Research Institutions
• 12.2. Government & Regulatory Organizations
• 12.3. Medical Device Companies
• 12.4. Pharmaceuticals & Biotechnology Companies

13. In Vivo CRO Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. In Vivo CRO Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. In Vivo CRO Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States In Vivo CRO Market

17. China In Vivo CRO Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Altogen Labs
• 18.6. Biocytogen Boston Corp.
• 18.7. Cellvax, SAS
• 18.8. Charles River Laboratories International, Inc.
• 18.9. Crown Bioscience, Inc.
• 18.10. Eurofins Scientific SE
• 18.11. Evotec SE
• 18.12. Explicyte by Immusmol SAS Company
• 18.13. GEMPHARMATECH LLC
• 18.14. ICON Plc
• 18.15. Imavita S.A.S.
• 18.16. IQVIA Holdings Inc.
• 18.17. IVRS AB
• 18.18. JSR Corporation
• 18.19. Labcorp Drug Development PRIVATE LIMITED
• 18.20. Medpace, Inc.
• 18.21. Melior Discovery Inc.
• 18.22. Noble Life Sciences Inc.
• 18.23. Parexel International Corporation
• 18.24. Pharmacology Discovery Services Ltd.
• 18.25. Pharmaron Beijing Co., Ltd.
• 18.26. Pharmatest Services Ltd.
• 18.27. PPD Inc. by Thermo Fisher Scientific, Inc.
• 18.28. PSI CRO AG
• 18.29. Syneos Health Inc.
• 18.30. Syngene International Limited
• 18.31. Taconic Biosciences, Inc.
• 18.32. WuXi AppTec, Inc.
• 18.33. Yecuris Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 100. AMERICAS IN VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 101. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 102. AMERICAS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 103. AMERICAS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 104. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 105. AMERICAS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 106. AMERICAS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 107. AMERICAS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 108. AMERICAS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 109. AMERICAS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 110. AMERICAS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 114. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 116. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 118. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 119. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 120. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 121. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 122. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 124. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 126. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 128. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 130. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 131. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 132. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 143. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 144. EUROPE IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 145. EUROPE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 146. EUROPE IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 147. EUROPE IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 148. EUROPE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 149. EUROPE IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 150. EUROPE IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 151. EUROPE IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 152. EUROPE IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 153. EUROPE IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 154. EUROPE IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 156. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 157. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 158. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 160. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 162. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 164. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 166. AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 167. AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 168. AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 169. AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 170. AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 171. AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 172. AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 173. AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 174. AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 175. AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 176. AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 177. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 178. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 180. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 182. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 184. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 186. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 188. GLOBAL IN VIVO CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 189. ASEAN IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 190. ASEAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 191. ASEAN IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 192. ASEAN IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 193. ASEAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 194. ASEAN IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 195. ASEAN IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 196. ASEAN IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 197. ASEAN IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 198. ASEAN IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 199. ASEAN IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 200. GCC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 201. GCC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 202. GCC IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 203. GCC IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 204. GCC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 205. GCC IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 206. GCC IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 207. GCC IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 208. GCC IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 209. GCC IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 210. GCC IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 211. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 212. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 213. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 214. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 215. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 216. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 218. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 219. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 220. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 221. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 222. BRICS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 223. BRICS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 224. BRICS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 225. BRICS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 226. BRICS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 227. BRICS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 228. BRICS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 229. BRICS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 230. BRICS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 231. BRICS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 232. BRICS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 233. G7 IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 234. G7 IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 235. G7 IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 236. G7 IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 237. G7 IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 238. G7 IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 239. G7 IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 240. G7 IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 241. G7 IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 242. G7 IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 243. G7 IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 244. NATO IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 245. NATO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 246. NATO IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 247. NATO IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 248. NATO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 249. NATO IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 250. NATO IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 251. NATO IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 252. NATO IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 253. NATO IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 254. NATO IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 255. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 256. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 257. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 258. UNITED STATES IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 259. UNITED STATES IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 260. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 261. UNITED STATES IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 262. UNITED STATES IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 263. UNITED STATES IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 264. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 265. UNITED STATES IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 266. UNITED STATES IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 267. CHINA IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 268. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 269. CHINA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 270. CHINA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
• TABLE 271. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 272. CHINA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
• TABLE 273. CHINA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
• TABLE 274. CHINA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
• TABLE 275. CHINA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
• TABLE 276. CHINA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
• TABLE 277. CHINA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)